Perspectives of COPD patients, publicly funded scientists, and industry representatives on responsibility and stakeholder engagement in drug discovery research

Figures & data

Table 1. Summary of key findings.

	COPD patients	Scientists	Industry representatives
How do they talk about their own responsibility?	Responsibility is linked to their own health behavior. Some are willing to embrace ‘more responsibility’ while others consider it stigmatizing.	Responsibility is linked to the integrity of their own research practices.	Responsibility is linked to running a sustainable business while developing drugs and the concept of Corporate Social Responsibility (CSR).
How do they want to engage with other stakeholders?	They do not expect or desire influence on drug development. They express trust in the process of drug development.	They do not desire direct contact with patients during drug development as they are concerned about raising false hope about the availability of new medication.	They do not desire involvement in the drug development process due to potential confidentiality issues.
How do they talk about the responsibility of other stakeholders?	They have concerns about prioritization of diseases in the research and health sectors.	They are concerned about funding structures, over-emphasized quests for impact, and tensions between patenting and open science.	They are concerned about increasing the pool of available research from universities, and marketization. They expect governments to regulate and incentivize responsibility.

Data availability statement

Participants did not consent to the sharing of their data, and as such the data supporting this publication are not publicly available.